There's no better use of healthcare marketing dollars than to reach patients with unmet needs. That's why niche marketing has gained steam during the last few
years. But increasing competition in accessing doctors who treat culturally and racially diverse patient groups means pharma
marketers have to refine their definition of what constitutes a niche market in the first place. In doing so, they may stumble
over a market that has not yet been saturated—US prisoners.
Market report. More than two million adults are incarcerated in the US, spread among federal, state, and juvenile facilities. (See "Potential
Market?") They are more likely than the general population to have conditions such as HIV, hepatitis C, and psychotic disorders.
In fact, they are three to four times more likely to suffer from serious mental illness, according to the US Department of
Physicians working in prisons are often not prison employees, according to Dilip Phadnis, chief executive of the Rowin Group,
which is undertaking a study on prison drug use. He says institutions often outsource clinical services to companies such
as Prison Health Services, which serves more than 300 correctional facilities in the United States.
Phadnis notes that prisons use a national formulary and three prescription benefit managers (Correctional Medical Systems,
Secure Pharma Plus, a sister company to Prison Health Service, and Diamond Drugs) cover nearly 700,000 prison lives.
Building momentum. More companies are making inroads into marketing to stakeholders who influence what drugs are used in jail. For example,
Pfizer included this market when it launched its anti-psychotic Geodon (ziprasidone) in 2001. And the National Council on
Correctional Health Care already reports many Big Pharma exhibitors—such as Abbott, AstraZeneca, Boehringer-Ingelheim, Janssen,
and Roche—for its annual meeting at which 2,000 correctional health professionals are expected to gather in November.
Moving forward. Prisons spend nearly $6 billion on healthcare each year, according to the Rowin Group, so opportunity abounds. So do questions—like
the rules governing the detailing of prison doctors. But careful market research, thoughtful education, and communication
with all stakeholders paves the way to make the most of this growing opportunity.